Table 3 Subgroup analysis for risk of outcomes associated with switchers vs. non-switchers in patients with cancer-associated venous thrombosis in six months

From: Effectiveness and safety of continuous low-molecular-weight heparin versus switching to direct oral anticoagulants in cancer-associated venous thrombosis

Subgroups

Non-Switchers (N)

Switchers (N)

Hospitalization due to VTE

Major bleeding

All-cause mortality

Adjusted Hazard Ratio (95% CI)

P value

Adjusted Hazard Ratio (95% CI)

P value

Adjusted Hazard Ratio (95% CI)

P value

Sex

Male

1236

739

0.51 (0.32–0.82)

0.005

0.91 (0.65–1.27)

0.563

0.67 (0.58–0.76)

5.08e-9

Female

1420

961

0.49 (0.31–0.77)

0.002

1.20 (0.88–1.64)

0.256

0.69 (0.61–0.78)

2.21e-9

Age

< = 65 years

1274

764

0.51 (0.32–0.82)

0.006

0.83 (0.58–1.18)

0.294

0.72 (0.62–0.83)

3.99e-6

>65 years

1382

936

0.46 (0.30–0.72)

7.11e-4

1.22 (0.90–1.65)

0.198

0.64 (0.57–0.73)

1.28e-12

Metastasis

No

1528

1009

0.58 (0.40–0.86)

0.006

1.23 (0.91–1.67)

0.178

0.60 (0.53–0.69)

2.11e-14

Yes

1128

691

0.33 (0.17–0.63)

7.42e-4

0.87 (0.62–1.23)

0.438

0.77 (0.67–0.87)

5.95e-5

Gastrointestinal malignancy

No

1883

1253

0.49 (0.33–0.70)

1.43e-4

1.08 (0.84–1.40)

0.552

0.66 (0.59–0.74)

1.40e-13

Yes

773

447

0.51 (0.26–1.00)

0.052

0.90 (0.55–1.49)

0.692

0.72 (0.61–0.85)

1.12e-4

Platinum treatment within 3 months before index date

No

2296

1453

0.46 (0.32–0.65)

1.06e-5

1.09 (0.85–1.39)

0.507

0.65 (0.59–0.71)

4.40e-18

Yes

360

247

0.79 (0.33–1.89)

0.600

0.85 (0.46-–1.55)

0.589

0.89 (0.70–1.13)

0.351

CCI

Low ( < 6)

1108

677

0.59 (0.35–0.98)

0.042

1.25 (0.87–1.81)

0.231

0.62 (0.53–0.72)

2.25e-9

High (> = 6)

1548

1023

0.42 (0.27–0.64)

5.06e-5

0.93 (0.69–1.25)

0.628

0.71 (0.64–0.80)

3.80e-9

Khorana risk score

Low ( < 2)

1049

809

0.49 (0.31–0.79)

0.003

1.11 (0.78–1.60)

0.557

0.67 (0.57–0.78)

1.22e-7

High (>=2)

1607

891

0.45 (0.29–0.71)

6.46e-4

1.01 (0.75–1.37)

0.955

0.68 (0.61–0.77)

1.95e-10

Bleeding risk

Low

718

517

0.44 (0.23–0.84)

0.013

1.68 (1.06–2.65)

0.026

0.57 (0.48–0.69)

5.97e-9

High

1938

1183

0.50 (0.34–0.72)

2.44e-4

0.91 (0.70–1.19)

0.486

0.71 (0.64–0.79)

1.74e-10

Treatment duration before switching

Shorter (< = 10 days)

2656

935

0.57 (0.38–0.85)

0.007

1.06 (0.80–1.41)

0.673

0.72 (0.64–0.81)

3.04e-8

Longer ( > 10 days)

2656

765

0.37 (0.22–0.60)

6.39e-5

1.06 (0.77–1.47)

0.704

0.64 (0.56–0.74)

3.70e-10

  1. N Number of patients, CI Confidence interval, VTE Venous thromboembolism, CCI Charlson comorbidity index. All P values were from 2-sided tests and results were deemed statistically significant at P < 0.05.
Back to article page